United States securities and exchange commission logo





                               June 3, 2022

       Zheng Wei, Ph.D.
       Chief Executive Officer
       Connect Biopharma Holdings Limited
       Science and Technology Park
       East R&D Building, 3rd Floor
       6 Beijing West Road, Taicang
       Jiangsu, the People   s Republic of China 215400

                                                        Re: Connect Biopharma
Holdings Limited
                                                            Amendment No. 1 to
Registration Statement on Form F-3
                                                            Filed May 23, 2022
                                                            File No. 333-264340

       Dear Dr. Wei:

              We have reviewed your amended registration statement and have the
following
       comment. In our comment, we may ask you to provide us with information
so we may better
       understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comment applies to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to this comment, we may have additional comments.
Unless we note
       otherwise, our references to prior comments are to comments in our April
27, 2022 letter.

       Amendment No. 1 to Registration Statement on Form F-3 filed May 23, 2022

       Our Company, page 3

   1.                                                   We acknowledge your
revised disclosure in response to prior comment 2 that you and
                                                        your PRC subsidiaries
are not subject to any permission requirements from the CSRC, the
                                                        CAC or other
governmental agency that is required for this offering and that your PRC
                                                        subsidiaries have
obtained all necessary licenses and approvals to conduct your operations
                                                        in China. Please advise
whether you relied on outside PRC counsel as the basis for your
                                                        belief that you are not
subject to the review or required to obtain prior approval, and if so,
                                                        file a consent.
 Zheng Wei, Ph.D.
Connect Biopharma Holdings Limited
June 3, 2022
Page 2

       Please contact Jane Park at 202-551-7439 or Jason Drory at 202-551-8342
with any
questions.



                                                         Sincerely,
FirstName LastNameZheng Wei, Ph.D.
                                                         Division of
Corporation Finance
Comapany NameConnect Biopharma Holdings Limited
                                                         Office of Life
Sciences
June 3, 2022 Page 2
cc:       Michael Sullivan, Esq.
FirstName LastName